glp 1 dual agonist The current significance and prospects for the use of receptor agonism GLP-1/Glucagon Effects of tirzepatide, a dual

This is standard practice across the industry and not unique to Simple Peptide

Available online at: (Accessed April 27, 2024)

Novo Nordisk announced FDA acceptance of their New Drug Application (NDA) for a 25 mg oral version of Wegovy for two new indications: (1) chronic weight management in adults living with obesity or who are overweight with at least one comorbid condition, and (2) to reduce the risk of MACE in adults with overweight or obesity and established CVD

Your primary care provider can help you decide if you are a good candidate for a GLP-1 and explain how the medication will fit into your overall care plan

Other New Stuff: The Genetics of G-Agonists In a seminal study of the genomics of glucose regulation in nearly 500,000 people, specific coding variants of the GLP-1 receptor (GLP1R) were associated with potential GLP-1 drug response

(1993) Glucagon-like peptide-1 (7-36)amide and glucose-dependent insulinotropic polypeptide secretion in response to nutrient ingestion in man: acute post-prandial and 24-h secretion patterns